Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of HyQvia (Immunoglobulin
10% with recombinant hyaluronidase) with conventional subcutaneous immunoglobulin treatment
in patients with Multifocal Motor Neuropathy (MMN).